Skip to content
Biodatica
Start free

iOnctura

Bari, Florence

OncologyPhase II
Compare Sign in to watch

What changed

Phase I trial registered: A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

1w agoTrial registeredJul 8, 2026Source filing (opens the source filing in a new tab)

Momentum

87no change

Momentum 87 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

1,843 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1/PHASE2 registered

    Nov 17, 2025

    Myelofibrosis (MF) · RECRUITING · sponsor: iOnctura · A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors

    ClinicalTrials.gov · NCT06887803 (opens the source filing in a new tab)

  2. Trial

    PHASE1/PHASE2 registered

    Apr 22, 2025

    Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Advanced Non Squamous NSCLC · ACTIVE_NOT_RECRUITING · sponsor: iOnctura · A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients

    ClinicalTrials.gov · NCT06879717 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    Feb 27, 2025

    Uveal Melanoma, Ocular Melanoma · ACTIVE_NOT_RECRUITING · sponsor: iOnctura · A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma

    ClinicalTrials.gov · NCT06717126 (opens the source filing in a new tab)

  4. Trial

    PHASE1 registered

    Feb 25, 2020

    Solid Tumor, Adult, Non-Hodgkin Lymphoma, Adult, NSCLC, Myelofibrosis, Uveal Melanoma · ACTIVE_NOT_RECRUITING · sponsor: iOnctura · A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

    ClinicalTrials.gov · NCT04328844 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources